I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04488081

Recruitment Status : Recruiting

First Posted : July 27, 2020

Last Update Posted : July 21, 2021

See Contacts and Locations

Sponsor:

Collaborators:

University of California, San Francisco

University of Pennsylvania

Emory University

University of Alabama at Birmingham

University of Colorado, Denver

University of Southern California

Yale University

Columbia University

Wake Forest University Health Sciences

Sanford Health

Long Beach Memorial Medical Center

Georgetown University

Kalispell Regional Medical Center

Montefiore Medical Center

University of California, Davis

Hoag Memorial Hospital Presbyterian

University of Iowa

Main Line Health

Northwestern University

Information provided by (Responsible Party):

QuantumLeap Healthcare Collaborative

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	July 24, 2022
Estimated Study Completion Date :	November 1, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD; ISPY COVID Adaptive Platform Trial Network; undefined. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. BMJ Open. 2022 Jun 6;12(6):e060664. doi: 10.1136/bmjopen-2021-060664.

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9:CD013825. doi: 10.1002/14651858.CD013825.pub2. Review.

To Top